Page 1

PYC Therapeutics April 30 , 2021 PYC Therapeutics Highlights Continued Progress of Ocular and CNS Pipeline Programs and U.S. Expansion in First Quarter Update Lead Candidate VP - 001 for Treatment of Retinitis Pigmentosa Type 11 Moves Closer to Clinical Development ; Larger Animal Model Readouts on Track for 2021 , with IND Submission Expected in mid 2022 First Preclinical Study in the CNS Shows Company's PPMO Technology Can Be Successfully Applied Across High Value Target Tissues Beyond The Eye ; Company Expects to Nominate CNS Candidate This Year Three U.S. - Based , Biopharma Industry Leaders Join Company to Drive Clinical Translation of Pipeline Programs , Including a Chief Development Officer and Board Directors ; More Executive Appointments Expected in the Coming Months PERTH , Australia and NEW YORK , New York April 30 , 2021 PYC Therapeutics ( ASX : PYC ) , a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases , today announced a first quarter update highlighting the progress of its development pipeline , growth of its U.S. operations and upcoming milestones . " PYC has had an exciting quarter of progress against our Company objectives . We have achieved continued validation of our PPMO technology in our lead candidate VP - 001 for retinitis pigmentosa type 11 , further development of our ocular pipeline as well as PYC's first set of preclinical data from our CNS discovery efforts demonstrating superior delivery of RNA therapeutic throughout the brain and spinal cord . The potential of our pioneering PPMO technology is vast and we look forward to advancing this technology to provide solutions for patients with inherited ocular and neurodegenerative diseases for whom treatment options are either limited or unavailable today , " said Sahm Nasseri , U.S. Chief Executive Officer of PYC Therapeutics . " This quarter , we also expanded our U.S. operations with key leadership appointments and engagements with the U.S. biotech ecosystem , underscoring the significant steps we are taking towards our transformational goal of becoming a multi - asset clinical stage biotechnology company . PYC is well positioned to maintain this momentum into the second quarter of 2021 with important larger animal studies commencing for VP - 001 , deeper development of VP - 002 and into the balance of 2021 with continued development of our pipeline in both the eye and the CNS . " " This is a transformational time for PYC . For some time , we've had significant excitement in our PPMO technology's potential for impact in treating numerous genetic and acquired diseases and it's truly humbling to see that excitement being translated into results through both our lead program development , and our technology's continued validation , " commented Alan Tribe , Chairman of PYC Therapeutics . +61 8 6151 0994 pyctx.com | ACN 098 391 961 1